Skip to content

Feasibility study of mindfulness-based cognitive therapy for anxiety disorders in a Japanese setting

Mitsuhiro Sado, Sunre Park, Akira Ninomiya, Yasuko Sato, Daisuke Fujisawa, Joichiro Shirahase, Masaru Mimura

BMC research notes September 6, 2018 DOI: 10.1186/s13104-018-3744-4 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Single-arm pre-post study Peer reviewed
Sample size 14
Population Adults aged 20-74 with a diagnosis of an anxiety disorder, mean age 45.0, 71.4% female
Intervention Mindfulness-based cognitive therapy (MBCT)
Duration 8 weekly 2-hour sessions followed by 2 monthly boosters; evaluations at baseline, mid-intervention, end of intervention, and follow-up
Measures State-Trait Anxiety Inventory (STAI)-state, STAI-trait
Topics Anxiety Meditation
Citations 16
Key points In 14 patients with anxiety disorders, MBCT was associated with statistically significant improvements in state anxiety at every assessment point and in trait anxiety from early stages, with some secondary outcomes also improving. The authors suggest MBCT may be effective even in a context of high pharmacotherapy rates, though the uncontrolled design limits conclusions.

Abstract

Objective: Mindfulness-based cognitive therapy (MBCT) could be a treatment option for anxiety disorders. Although its effectiveness under conditions of low pharmacotherapy rates has been demonstrated, its effectiveness under condition of high pharmacotherapy rate is still unknown. The aim of the study was to evaluate effectiveness of MBCT under the context of high pharmacotherapy rates.

Results: A single arm with pre-post comparison design was adopted. Those who had any diagnosis of anxiety disorders, between the ages of 20 and 74, were included. Participants attended 8 weekly 2-hour-long sessions followed by 2 monthly boosters. Evaluation was conducted at baseline, in the middle, at end of the intervention, and at follow-up. The State-Trait Anxiety Inventory (STAI)-state was set as the primary outcome. Pre-post analyses with mixed-effect models repeated measures were conducted. Fourteen patients were involved. The mean age was 45.0, and 71.4% were female. The mean change in the STAI-state at every point showed statistically significant improvement. The STAI-trait also showed improvement at a high significance level from the very early stages. The participants showed significant improvement at least one point in some other secondary outcomes. Trial registration Retrospectively registered at the University Hospital Medical Information Network on 1st August 2013 (ID: UMIN000011347).

Comparable studies

Other non-randomized and open-label trials on anxiety, most cited first.

Study Year Design Participants
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder Subjects with obsessive-compulsive disorder (OCD) 2006 Controlled clinical trial
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Emotions and brain function are altered up to one month after a single high dose of psilocybin. Healthy volunteers (7 female, 5 male) 2020 Open-label pilot study n = 12
Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study Older long-term AIDS survivor (OLTAS) self-identified gay men with moderate-to-severe... 2020 Open-label study

Citations in the library

Explore topics